Dhingra Ankur 4
4 · Summit Therapeutics Inc. · Filed Dec 13, 2023
Insider Transaction Report
Form 4
Dhingra Ankur
Chief Financial Officer
Transactions
- Purchase
Common Stock
2023-12-13$2.15/sh+700$1,505→ 235,258 total(indirect: By Trust) - Purchase
Common Stock
2023-12-13$2.17/sh+19,700$42,749→ 254,958 total(indirect: By Trust)
Footnotes (2)
- [F1]The Reporting Person purchased these shares in a single transaction on the open market.
- [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.